Related Experiment Video
Updated: Aug 19, 2026

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
Published on: June 29, 2015
Inhibitory effect of probucol on nephrotoxicity induced by ferric nitrilotriacetate (Fe-NTA) in rats
1Department of Pathology, Faculty of Medicine, University of Tokyo, Japan.
Abstract:
Effects of dietary probucol on renal damage induced by a renal carcinogen, ferric nitrilotriacetate (Fe-NTA), in male Wistar rats were quantitatively investigated with a computer-mediated image analyzer. The kidneys of rats fed a 1% probucol diet were protected from necrosis and lipid peroxidation induced by a single i.p. treatment with Fe-NTA solution at 5 mg Fe/kg body wt and were significantly resistant to a higher dose. For the parameter of lipid peroxidation, Schiff's staining method was utilized to demonstrate the extent of formation of aldehydes, products of lipid peroxidation. Thus following injection of Fe-NTA solution at 10 mg Fe/kg body wt the average areas of tubular necrosis were 85.8% versus 56.9% and the positive areas for Schiff's staining were 15.3% versus 5.6% in the renal cortices of rats fed control of 1% probucol diets respectively. These results indicate that probucol provides protection against Fe-NTA-induced nephrotoxicity through its antioxidant properties. In addition to being a cholesterol-lowering drug, useful for the control of hypercholesterolemia, probucol may therefore be beneficial for prevention and treatment of various pathogenic processes including those leading to carcinogenesis.
Related Concept Videos
Drug Elimination by Renal Route: Tubular Reabsorption
Drug Elimination by Renal Route: Tubular Secretion
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Acute Kidney Injury IV: Diagnostic Studies and Prevention

